Bayer is pressing ... given alongside aspirin plus a P2Y12 inhibitor – at one year. Once again, there was no significant observed increase in bleeding with asundexian at any dose or compared ...

"Biomarker studies and a planned prospective meta-analysis with similar ongoing aspirin trials will help to confirm or exclude efficacy. These could be impactful globally given the low cost of ...

As low-dose prophylactic aspirin therapy becomes common among older people, potential risks that are associated with such treatment assume increasing importance. In particular, some clinicians are ...

Description The goal of the trial was to evaluate treatment with famotidine compared with placebo among patients taking low-dose aspirin. Hypothesis Famotidine would be more effective in ...

Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.

A new publication in the British Medical Journal reviewed current clinical data and found NSAIDs like Aleve and Bayer Aspirin ...

Patients treated with the high dose reported more adverse events than those on the low dose (23.4% vs 12.1%). Low-dose doxycycline proved to be equally as effective as high-dose doxycycline for ...

Study investigators also assessed whether the low dose resulted in a decreased risk of bleeding compared with a full dose. In this randomized, international, double-blinded study, a total of 1,766 ...

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...

Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in ...

Bayer has claimed EU approval for Kerendia ... progression or renal death by 18% when added to the highest tolerated dose of standard therapy. The drug also cut cardiovascular outcomes ...